Oncology | Phase I Developments | CHINA

Transcenta Holding

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US

Lead Product(s): TST001

Therapeutic Area: Oncology Product Name: TST001

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2020

Details:

The Phase I clinical trial conducted in the US aims to evaluate TST001 in the treatment of patients with advanced or metastatic solid tumors. The primary objectives of the study are to evaluate TST001's safety, tolerability and recommended dose for Phase II study.

InxMed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

InxMed Released Research Data of "FAK inhibitor IN10018 Overcomes Drug Resistance of KRAS G12C Inhibition" at 2020 AACR Annual Meeting

Lead Product(s): IN10018,Cobimetinib

Therapeutic Area: Oncology Product Name: IN10018

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2020

Details:

The combination of KRAS G12C inhibitors and IN10018 induced FAK signaling by KRAS G12C inhibition, serving as one predominant mechanism of drug resistance of KRAS G12C inhibition, and IN10018 significantly decreases the FAK signaling induced by KRAS G12C inhibition.

ABM Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA

Lead Product(s): ABM-1310

Therapeutic Area: Oncology Product Name: ABM-1310

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

The first cancer patient has been successfully enrolled and dosed with ABM-1310 in the Phase 1. It demonstrated superior properties in pre-clinical animal models, is a highly selective, highly water-soluble, orally active, and brain-penetrant small molecule BRAF inhibitor.

Innovent Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study

Lead Product(s): IBI310,Sintilimab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2020

Details:

The study is an open-label study and was consisted of two parts, Phase 1a study and Phase 1b study, designed to evaluate the tolerability, safety and anti-tumor activity of IBI310 and its combination with sintilimab in the treatment of subjects with advanced malignant tumors.

Innovent Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study

Lead Product(s): IBI318

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

The preliminary results from study show that IBI318, a first-in-class bispecific antibody, has an acceptable safety profile. We are hopeful to see positive results from the following studies to help more patients in need.

Ascentage Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates

Lead Product(s): Palcitoclax

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 31, 2020

Details:

Company is going to present four posters of the latest clinical data on three of its drug candidates, including the MDM2-p53 inhibitor APG-115, novel Bcl-2/Bcl-xL dual inhibitor palcitoclax or APG-1252, and IAP inhibitor APG-1387.

Gracell Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)

Lead Product(s): GC027

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

Both presentations is based on Gracell’s TruUCAR™ GC027 in relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) patients and Enhanced CAR GC008t in patients with advanced mesothelin-positive solid tumors.

Transcenta Holding

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

Transcenta Presents Data from Phase 1 Study of MSB2311 in Pre-treated Advanced Solid Tumors and Select Hematological Malignancies

Lead Product(s): MSB2311

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

Initial results suggest a favorable safety profile across all MSB2311 doses evaluated. Investigators reported that patients achieved durable responses which persisted with one durable beyond 12 months at the time of this press release.

Innovent Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China

Lead Product(s): IBI939

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2020

Details:

CIBI939A101 is a Phase 1 clinical study conducted in China to evaluate IBI939 in the treatment of patients with advanced malignancies.

Transcenta Holding

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

INTERPHEX 2020

Participation Not Confirmed

Update your events

Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II

Lead Product(s): TST001

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Transcenta will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal antibody developed by its subsidiary Mabspace Biosciences, in a poster during the 2020 American Association for Cancer Research.

Find

Find Oncology Drugs in Phase I Clinical Development in CHINA

China

Product Type

Companies

Transcenta Holding

Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US

InxMed

InxMed Released Research Data of "FAK inhibitor IN10018 Overcomes Drug Resistance of KRAS G12C Inhibition" at 2020 AACR Annual Meeting

ABM Therapeutics

ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA

Innovent Biologics

Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study

Innovent Biologics

Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study

Ascentage Pharma

Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates

Gracell Biotechnologies

Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)

Transcenta Holding

Transcenta Presents Data from Phase 1 Study of MSB2311 in Pre-treated Advanced Solid Tumors and Select Hematological Malignancies

Innovent Biologics

Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China

Transcenta Holding

Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II